BioCardia® receives award from the Maryland Stem Cell Research Fund for CardiAMP cell therapy program for the treatment of ischemic heart failure
May 23, 2016
SAN CARLOS, CA – BioCardia, Inc., a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, announced today that it has received a $750,000 grant from the Maryland Stem Cell Research Fund (MSCRF) to support the CardiAMP cell therapy program for the treatment of ischemic heart failure.
“We are excited to receive this prestigious award to support our heart failure program and thank the MSCRF for their review and consideration. This grant underscores the value of our unique capabilities to both identify the patients most likely to be responsive to CardiAMP cell therapy using a pre-procedure marrow potency assay, and to perform cell collection, cell processing, and cell delivery to the areas of injury in the patient’s heart in a 60 to 90 minute procedure,” said Peter A. Altman, PhD, Chief Executive Officer of BioCardia. “Importantly, this project supports our continued commitment to advancing the CardiAMP cell therapy program for the treatment of patients with heart failure who have few options.”
The Company’s CardiAMP cell therapy system is currently under investigation in a Phase 3 study for the treatment of heart failure. The Food and Drug Administration (FDA) has approved the trial under an Investigational Device Exemption (IDE). The Centers for Medicaid and Medicare Services (CMS) have approved this IDE Nationally as qualified for CMS reimbursement.
About the Maryland Stem Cell Research Fund
Established by the Governor and the Maryland General Assembly through the Maryland Stem Cell Research Act of 2006, the Maryland Stem Cell Research Fund (MSCRF) promotes State funded stem cell research and cures through grants and loans to both public and private entities in Maryland.
BioCardia, Inc., headquartered in San Carlos, CA is a privately held company developing regenerative biologic therapies to treat cardiovascular disease. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
Miranda Peto Benvenuti
email@example.com | 650-226-0120
Cell & Gene
The Big Biz show
CALL US NOW
EMAIL US NOW